By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Allele Biotech on Friday announced that it has signed a contract with the National Cancer Institute to conduct RNAi screening aimed at identifying synthetic targets for killing cancer cells.

The San Diego-based firm will use its high-quality fluorescent proteins, lentivirus systems, and shRNA platform for the project. It noted that the University of Florida is a sub-contractor on the contract.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.